PLOD2 is upregulated in various cancers and is associated with poor outcomes in bladder cancer [13], hepatocellular carcinoma [14,15] and breast cancer [16] (and reviewed in [17]). This evidence concerns the gene PLOD2 and urinary bladder cancer.